Altamira Therapeutics Ltd.
CYTOF
$0.0999
-$0.01-9.10%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 82.61% | 80.42% | 78.58% | 37.89% | -25.87% |
| Total Depreciation and Amortization | -52.20% | -49.64% | -47.60% | -20.82% | 6.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.65% | -94.12% | -92.59% | -19.77% | 393.91% |
| Change in Net Operating Assets | 127.18% | -252.59% | -197.57% | -202.69% | -216.94% |
| Cash from Operations | 72.52% | 43.74% | 7.85% | 17.61% | 24.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.09% | 100.03% | 100.01% | 88.25% | 80.46% |
| Cash from Investing | 100.09% | 100.03% | 100.01% | 88.25% | 80.46% |
| Total Debt Issued | -- | -72.11% | -54.60% | -40.75% | -23.99% |
| Total Debt Repaid | 68.23% | 28.72% | -50.79% | -112.25% | -205.18% |
| Issuance of Common Stock | -68.41% | -29.70% | 52.06% | 68.77% | 83.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 75.31% | 15.95% | -230.55% | -83.29% | -35.23% |
| Cash from Financing | -78.76% | -50.46% | -18.82% | 0.50% | 19.71% |
| Foreign Exchange rate Adjustments | -83.07% | -46.81% | 132.92% | 4,526.32% | 649.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.48% | 53.02% | 103.80% | 96.92% | 96.18% |